Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality. A new study suggests a risk prediction model that may identify of high-risk patients to promote timely diagnosis and treatment.
Dr. John Cush RheumNow
1 year 7 months ago
Growing Physician Enthusiasm for AI in Healthcare
The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.
https://t.co/7nGn5XsfEI https://t.co/sH3yQtaQue
Dr. John Cush RheumNow
1 year 7 months ago
The Cartel is Coming for Rheumatology
At first glance, the pharmaceutical marketplace may not appear like a crime drug ring, but Dr. Feldman of Tulane University described how sinister forces of market manipulation have negatively impacted patient care for years.… https://t.co/nOllJFR9AQ https://t.co/IxyGaysOEe
Dr. John Cush RheumNow
1 year 7 months ago
Japanese study of 781 RA pts (78 dx w/ ILD; most UIP pattern). Mortality higher in RA-ILD (SMR 2.09) vs RA (1.16) vs gen population. Mortality increased w/ ILD (adj HR 2.97), advanced age (1.08/per yr) , and low BMI (3.07) https://t.co/EYKfHotZPr https://t.co/xC6E0OLfFs
Dr. John Cush RheumNow
1 year 7 months ago
Combination biologics in PsA: are we there yet?
Combination therapy is well-established in rheumatoid arthritis, but its efficacy in psoriatic arthritis (PsA) remains uncertain. Despite effective treatment options, there is a need for solutions for patients unresponsive to… https://t.co/uqLnxLIktM https://t.co/awwaVPOZTu
Dr. John Cush RheumNow
1 year 7 months ago
February 5, 2025, the FDA granted Fast Track designation to ADI-001, an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory class III or class IV lupus nephritis, & nd SLE with extrarenal Dz… https://t.co/ywXUTKSoB2 https://t.co/Es0F63MBrk
Dr. John Cush RheumNow
1 year 7 months ago
JAMA Review on Dx & Rx of Monoclonal Gammopathy of Undetermined Significance. MGUS has NO Sxs or organ damage. MGUS & Dz associations (OP, Autoimmune) were likely overestimated; M protein testing should be done if malignancy or MGCS is suspected. Risk of progression to malignancy… https://t.co/Jikc5q3BJL https://t.co/hxhcD4bJ2X
Dr. John Cush RheumNow
1 year 7 months ago
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
https://t.co/EDCqmtbkyC https://t.co/2GlrslkgGp
The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.
Dr. John Cush RheumNow
1 year 7 months ago
That's not my problem - or is it? Multimorbidity in RA
RA can look so easy on the television commercials where patients appear young, healthy, and vibrant on the advertised treatment.
https://t.co/4lSVKeRtyx https://t.co/Xa1UGbJigy
Dr. John Cush RheumNow
1 year 7 months ago
SLE pts have increased risk of atherosclerotic cardiovascular disease (ASCVD). Systemic inflammation & glucocorticoid exposure are significant drivers of ASCVD in SLE. Screening recommended - Framingham Risk Score, ACC/AHA risk score & others reviewed https://t.co/jJHNJOU606 https://t.co/JJxiBczMwi
Dr. John Cush RheumNow
1 year 7 months ago
Prevalence of Systemic sclerosis–associated interstitial lung disease (SSc-ILD) was 49.8% - Chinese study of 223 SSc (F/U 8.1 yrs). Among SSc-ILD, 64% had progressive disease w/ elevated CRP at Dx as predictor. Overall mortality rate = 24.2% (pneumonia) w/ predictors of age,… https://t.co/Lb98KziPOj
Dr. John Cush RheumNow
1 year 7 months ago
Full read review of association betw #RA & Chikungunya fever (viral infxn transmitted by Aedes mosquitoes). Theres no true link betw RA & CHIKV; but incidence of RA after CHIKV is 13.7% (based on 16 reports, 2879 pts, 449 RA postCHIKV) https://t.co/8fxIS846Nd https://t.co/YD1aLIVrrI
Dr. John Cush RheumNow
1 year 7 months ago
NRMP Publishes 2025 Match Results. Rheumatology Stats:
- Ped Rheum #5 in # U.S. DO grads (30%)
- Adult Rheum #5 in Intl Med school grads (34%)
- Adult: 3/132 progr. went unfilled (Ped: 20/36 unfilled)
https://t.co/AsfOZMydMK https://t.co/Dim3hCLzXC
